Evobrutinib
Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50 of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases[1].
Product Specifications
CAS Number
[1415823-73-2]
Product Name Alternative
M2951; MSC2364447C
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Btk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/Evobrutinib.html
Purity
99.60
Solubility
DMSO : 33.33 mg/mL (ultrasonic)
Smiles
C=CC(N1CCC(CNC2=NC=NC(N)=C2C3=CC=C(OC4=CC=CC=C4)C=C3)CC1)=O
Molecular Formula
C25H27N5O2
Molecular Weight
429.51
Precautions
H315, H319, H335
References & Citations
[1]Caldwell R, et al. Discovery of Evobrutinib: An Oral, Potent and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019 Aug 1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6182412-01 0.1 mL
CBFA2T2 (Core-Binding Factor, Runt Domain, alpha Subunit 2; Translocated to, 2, DKFZp313F2116, EHT, MTGR1, ZMYND3) (HRP)
Ask
View Details 
MBS6182412-02 5x 0.1 mL
CBFA2T2 (Core-Binding Factor, Runt Domain, alpha Subunit 2; Translocated to, 2, DKFZp313F2116, EHT, MTGR1, ZMYND3) (HRP)
Ask
View Details